CRON · Cronos Group Inc.
$2.86
+0.01 (+0.35%)
At close · Jul 29
Market Cap
$1.06B
Shares
373.66M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$146.59M
+24.6%
FY2025
Net Income
-$9.45M
-123%
FY2025
Gross Margin
42.81%
+21.4pp
FY2025
Operating Margin
-11.87%
+53.2pp
FY2025
Diluted EPS
-$0.02
-118.2%
FY2025
Operating Cash Flow
$25.87M
+37.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $159.54M | $146.59M | $117.62M | $87.24M | $91.9M | $74.44M | $46.72M | $23.75M | |
| $68.18M | $62.76M | $25.2M | $11.91M | $11.97M | -$17.53M | -$25.83M | -$17.86M | |
| — | 42.81% | 21.42% | 13.65% | 13.02% | -23.56% | -55.29% | -75.22% | |
| $5.07M | $4.45M | $4.23M | $5.84M | $13.38M | $23.33M | $20.37M | $12.16M | |
| $22.81M | $21.76M | $21.6M | $22.7M | $22.28M | $44.94M | $34.39M | $23.05M | |
| $44.43M | $42M | $46.51M | $49.48M | $71.18M | $96.48M | $80.53M | $49.37M | |
| — | — | — | $3.51M | $2.75M | $1.8M | $814K | $646K | |
| $15.12M | $14.23M | $9.34M | $8.11M | $13.12M | $15.4M | $7.05M | $3.91M | |
| $1.97M | $2.04M | $630K | — | — | $0 | $7.27M | $889K | |
| $83.33M | $80.15M | $101.73M | $96.71M | $136.81M | $543.06M | $153.51M | $103.62M | |
| -$15.16M | -$17.4M | -$76.53M | -$84.8M | -$124.84M | -$560.59M | -$179.35M | -$121.48M | |
| — | -11.87% | -65.07% | -97.2% | -135.84% | -753.13% | -383.88% | -511.51% | |
| -$38K | -$3.16M | -$67.19M | -$76.69M | -$111.72M | -$545.19M | -$172.3M | -$117.57M | |
| — | — | — | — | $13K | $27K | $186K | $1.24M | |
| — | — | — | — | $22.55M | $9.1M | $18.6M | $29.23M | |
| $8.91M | $275K | $113.12M | $11.13M | -$9.72M | $163.46M | $106.07M | $1.29B | |
| — | $0 | $2.37M | $1.58M | $3.11M | -$6.31M | -$4.51M | -$2.01M | |
| — | -$446K | -$3.84M | -$10.51M | $17.85M | — | — | — | |
| -$6.25M | -$17.12M | $36.59M | -$73.67M | -$134.56M | -$397.14M | -$73.27M | $1.17B | |
| -$11.31M | -$14.19M | -$3.44M | -$3.23M | $34.18M | -$431K | $1.35M | $0 | |
| -$3.05M | -$9.45M | $41.08M | -$73.96M | -$168.73M | -$396.11M | -$73.14M | $1.17B | |
| — | -6.44% | 34.93% | -84.78% | -183.6% | -532.15% | -156.55% | 4911.6% | |
| $6.88M | $6.52M | -$1.06M | -$590K | $0 | -$1.1M | -$2.13M | -$932K | |
| -$309.84M | — | — | — | — | — | -$72.49M | $1.17B | |
| $30.71M | $37.24M | -$43.12M | -$52.49M | -$219.4M | -$389.24M | -$57.98M | $1.2B | |
| USD/shares | — | -$0.02 | $0.11 | -$0.19 | — | -$1.07 | -$0.21 | $3.76 |
| USD/shares | — | -$0.02 | $0.11 | -$0.19 | — | -$1.07 | -$0.21 | $3.33 |
| shares | — | 383.47M | 382.06M | 380.96M | 376.96M | 370.39M | 351.58M | 310.07M |
| shares | — | 383.47M | 385.56M | 380.96M | 376.96M | 370.39M | 351.58M | 342.81M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.69×
EV/EBIT
—
Peer median 27.62×
P/E (TTM)
—
Peer median 19.35×
Peer medians compare against the 47 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Rest of World Segment | $86,749,000 | $64,561,000 | $37,224,000 | $20,386,000 | $12,121,000 |
| United States Segment | $5,155,000 | $9,874,000 | $9,495,000 | $3,364,000 | $0 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Canada | $90,330,000 | $82,437,000 | $64,702,000 | $56,233,000 | $50,294,000 | $34,538,000 | $20,202,000 |
| Israel | $41,796,000 | $28,368,000 | $21,134,000 | $30,516,000 | $13,376,000 | $2,539,000 | — |
| Other Countries | $14,461,000 | $6,810,000 | $1,405,000 | $0 | $891,000 | $147,000 | $184,000 |
| United States | — | — | — | — | — | $9,495,000 | $3,364,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cannabis Flower | $108,476,000 | $87,912,000 | $62,070,000 | $63,593,000 | $55,194,000 | $27,932,000 | $15,020,000 | $9,210,000 |
| Cannabis Extracts | $37,700,000 | $29,168,000 | $24,569,000 | $22,522,000 | $8,807,000 | $18,254,000 | $8,702,000 | $2,732,000 |
| Product And Service Other | $411,000 | $535,000 | $602,000 | $634,000 | $560,000 | $533,000 | $28,000 | $179,000 |
Key facts
CIK
1656472
CUSIP
22717L101
13F (30d)
51 filings
51 filers
Visit website
Investor relations